BRCA2 and cancer: Generation of inhibitors to proteins like SMARCAL1 and ZRANB3 could be beneficial for treating cancer with defects in HR since their knockdown reduced the level of chromosomal instability in BRCA2-deficient cells exposed to clastogenic agents [140].